4.5 Article

Differential regulation of the interferon response in systemic lupus erythematosus distinguishes patients of Asian ancestry

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Medicine, General & Internal

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)

Michelle Petri et al.

Summary: Baricitinib, an oral inhibitor of Janus kinase 1 and 2, was evaluated as a treatment for patients with systemic lupus erythematosus (SLE) in a 52-week phase 3 study. The study found that baricitinib did not significantly improve SLE disease activity compared with placebo, and there were no new safety concerns.

LANCET (2023)

Article Multidisciplinary Sciences

Molecular pathways identified from single nucleotide polymorphisms demonstrate mechanistic differences in systemic lupus erythematosus patients of Asian and European ancestry

Katherine A. Owen et al.

Summary: Systemic lupus erythematosus (SLE) is a genetic autoimmune disorder that is more severe in individuals of Asian-Ancestry (AsA) compared to individuals of European-Ancestry (EA). This study examined the genetic associations and molecular pathways in SLE patients from different ancestries. The results showed that AsA patients had elevated oxidative stress, altered metabolism, and mitochondrial dysfunction, while EA patients had a robust interferon response related to nucleic acid sensing. The findings suggest that understanding ancestry-related molecular pathways may help explain the clinical severity differences in SLE patients.

SCIENTIFIC REPORTS (2023)

Article Rheumatology

Anti-RNP antibodies are associated with the interferon gene signature but not decreased complement levels in SLE

Erika L. Hubbard et al.

Summary: The study found complex relationships between anti-nuclear antibodies (ANA), complement, and the interferon gene signature (IGS) in the pathogenesis of systemic lupus erythematosus (SLE), with differences between different ancestral populations. Anti-RNP was more associated with African ancestry patients, while both anti-dsDNA and RNP were more associated with European ancestry patients. Additionally, the relationship between anti-RNP and complement was weak, while the relationship between anti-dsDNA and complement was strong.

ANNALS OF THE RHEUMATIC DISEASES (2022)

Article Immunology

High Interferon Signature Leads to Increased STAT1/3/5 Phosphorylation in PBMCs From SLE Patients by Single Cell Mass Cytometry

Gloria Yiu et al.

Summary: This study investigates the role of interferon (IFN) signaling in systemic lupus erythematosus (SLE). The results show a correlation between IFN signaling and clinical manifestations as well as immune factors in SLE, suggesting potential targets for future therapeutic approaches.

FRONTIERS IN IMMUNOLOGY (2022)

Article Rheumatology

Type 1 interferon status in systemic lupus erythematosus: a longitudinal analysis

Melissa Northcott et al.

Summary: This study found that ISG levels are stable over time in the majority of SLE patients and do not correlate with disease activity, although IFN high status is associated with more severe SLE. High-dose glucocorticoids can suppress ISG expression, while routine dose does not.

LUPUS SCIENCE & MEDICINE (2022)

Article Rheumatology

Biological insights into systemic lupus erythematosus through an immune cell-specific transcriptome-wide association study

Xianyong Yin et al.

Summary: By combining genome-wide association studies and transcriptome-wide association studies, we identified candidate genes associated with systemic lupus erythematosus and discovered a strong association between the CD83 gene and SLE. We also identified 276 gene candidates at the 110 SLE loci and demonstrated a regulatory effect of a putative causal variant on the ACAP1 gene.

ANNALS OF THE RHEUMATIC DISEASES (2022)

Article Rheumatology

Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis

Philip J. Mease et al.

Summary: This study evaluated the efficacy and safety of deucravacitinib, a selective TYK2 inhibitor, in patients with active PsA. The results showed that treatment with deucravacitinib led to significant improvements in ACR-20 response, multiplicity-controlled secondary endpoints, and other exploratory efficacy measures. The treatment was well tolerated.

ANNALS OF THE RHEUMATIC DISEASES (2022)

Article Biochemistry & Molecular Biology

Distinct transcriptome architectures underlying lupus establishment and exacerbation

Masahiro Nakano et al.

Summary: This study conducted a large-scale transcriptome analysis to understand the dysregulated gene expression patterns in systemic lupus erythematosus (SLE). The researchers identified cell-type-specific transcriptomic signatures associated with disease establishment and exacerbation. The study suggested the clinical value of disease-activity signatures in predicting organ involvement and therapeutic responses.
Article Multidisciplinary Sciences

Comprehensive transcriptomic analysis of COVID-19 blood, lung, and airway

Andrea R. Daamen et al.

Summary: Analysis of gene expression data from COVID-19 patients revealed that the inflammatory response is mainly driven by populations of myeloid-lineage cells. Delayed virus clearance may lead to exaggerated activation of these cells, contributing to disease pathogenesis through the production of inflammatory mediators.

SCIENTIFIC REPORTS (2021)

Article Biology

Transcriptomic analysis of immune cells in a multi-ethnic cohort of systemic lupus erythematosus patients identifies ethnicity- and disease-specific expression signatures

Gaia Andreoletti et al.

Summary: Gaia Andreoletti et al. leverage cell-sorted RNA-seq data and machine learning to investigate gene expression patterns in immune cell subtypes purified from Asian and White patients with a medical diagnosis of systemic lupus erythematosus (SLE). They report distinct clinical subtypes of SLE and identify ethnicity- and disease-specific gene clusters, potentially contributing toward the future development of personalized therapeutic strategies for patients with SLE.

COMMUNICATIONS BIOLOGY (2021)

Article Medicine, General & Internal

Trial of Anifrolumab in Active Systemic Lupus Erythematosus

Eric F. Morand et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Article Medicine, Research & Experimental

Patient ancestry significantly contributes to molecular heterogeneity of systemic lupus erythematosus

Michelle D. Catalina et al.

JCI INSIGHT (2020)

Article Medicine, Research & Experimental

Inhibition of IRF5 hyperactivation protects from lupus onset and severity

Su Song et al.

JOURNAL OF CLINICAL INVESTIGATION (2020)

Review Genetics & Heredity

Population genomics of East Asian ethnic groups

Ziqing Pan et al.

HEREDITAS (2020)

Article Rheumatology

Points to consider for skin ulcers in systemic sclerosis

Felice Galluccio et al.

RHEUMATOLOGY (2017)

Review Immunology

Regulation of type I interferon responses

Lionel B. Ivashkiv et al.

NATURE REVIEWS IMMUNOLOGY (2014)

Article Rheumatology

Association of a Functional IRF7 Variant With Systemic Lupus Erythematosus

Qiong Fu et al.

ARTHRITIS AND RHEUMATISM (2011)

Article Immunology

Evolutionary genetic dissection of human interferons

Jeremy Manry et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2011)